Summary
Multiple claims are about Lipitor (atorvastatin) and various safety outcomes from co-administration with Lipitor; however, the supplied FDA label excerpts are for a different product (Aspirin and Extended-Release Dipyridamole Capsules) and do not contain any Lipitor/atorvastatin-specific information. Therefore, nearly all drug-specific interaction/safety claims are unsupported relative to the provided prescribing information.
Category Scores
Accurate Statements
Taking aspirin with Lipitor can reduce the risk of heart attack in people who are at high risk.
Not supported by the supplied label excerpts (provided label indicates reduction of stroke risk in patients with TIA or completed ischemic stroke due to thrombosis, Section 1).
Unsupported Statements
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels.
No Lipitor (atorvastatin) information is present in the supplied prescribing information excerpts (provided document sections are for Aspirin and Extended-Release Dipyridamole Capsules).
Lipitor is used to prevent heart disease.
No Lipitor/atorvastatin indications are present in the supplied prescribing information excerpts.
Lipitor works by inhibiting the production of cholesterol in the liver.
No Lipitor mechanism information is present in the supplied prescribing information excerpts.
Lipitor reduces low-density lipoprotein (LDL) cholesterol.
No Lipitor LDL information is present in the supplied prescribing information excerpts.
Aspirin (acetylsalicylic acid, ASA) is a nonsteroidal anti-inflammatory drug (NSAID).
The supplied prescribing information excerpts do not define aspirin as an NSAID.
Aspirin is used to reduce pain, inflammation, and fever.
The supplied prescribing information excerpts provided are limited to stroke-risk reduction indications and do not describe aspirin analgesic/antipyretic/anti-inflammatory uses.
Aspirin works by blocking the production of prostaglandins.
No aspirin mechanism of action details are present in the supplied prescribing information excerpts.
Taking aspirin with Lipitor can increase the risk of bleeding.
No Lipitor/atorvastatin interaction information is present in the supplied prescribing information excerpts.
The risk of bleeding with aspirin plus Lipitor is increased particularly in people taking high doses of aspirin.
No such co-administration risk statements are present in the supplied prescribing information excerpts.
The risk of bleeding with aspirin plus Lipitor is increased particularly in people with a history of bleeding disorders.
No such co-administration risk statements are present in the supplied prescribing information excerpts.
Taking aspirin with Lipitor can increase the risk of kidney damage.
No Lipitor/atorvastatin interaction information or kidney-damage risk statements are present in the supplied prescribing information excerpts.
The risk of kidney damage with aspirin plus Lipitor is increased particularly in people with pre-existing kidney disease.
No such co-administration risk statements are present in the supplied prescribing information excerpts.
Taking aspirin with Lipitor can increase the risk of muscle damage.
No Lipitor/atorvastatin interaction information or muscle-damage risk statements are present in the supplied prescribing information excerpts.
The risk of muscle damage with aspirin plus Lipitor is increased particularly in people taking high doses of Lipitor.
No such co-administration risk statements are present in the supplied prescribing information excerpts.
The risk of muscle damage with aspirin plus Lipitor is increased particularly in people with a history of muscle problems.
No such co-administration risk statements are present in the supplied prescribing information excerpts.
Taking aspirin with Lipitor can increase the risk of liver damage.
No Lipitor/atorvastatin interaction information or liver-damage risk statements are present in the supplied prescribing information excerpts.
The risk of liver damage with aspirin plus Lipitor is increased particularly in people with pre-existing liver disease.
No such co-administration risk statements are present in the supplied prescribing information excerpts.
Taking aspirin with Lipitor can reduce the risk of heart attack in people who are at high risk.
Supplied label excerpts discuss reducing stroke risk (Section 1) and do not mention heart attack prevention.
Taking aspirin with Lipitor can reduce the risk of stroke in people who are at high risk.
While the supplied label indicates stroke-risk reduction in patients with TIA or completed ischemic stroke due to thrombosis (Section 1), the claim is framed as 'high risk' and includes Lipitor co-administration; no Lipitor-specific information is provided.
Aspirin can help to improve blood flow.
No such statement is present in the supplied prescribing information excerpts.
Aspirin can reduce inflammation.
No such statement is present in the supplied prescribing information excerpts.
Taking aspirin with Lipitor can provide benefit for people with heart disease or peripheral artery disease.
No indications for heart disease or peripheral artery disease are present in the supplied label excerpts.
Taking a lower dose of aspirin can reduce the risk of bleeding and other side effects.
No dosing-versus-bleeding-risk guidance is provided in the supplied label excerpts.
Clopidogrel and prasugrel are antiplatelet medications that can be used in place of aspirin.
No information about clopidogrel/prasugrel substituting for aspirin is present in the supplied prescribing information excerpts.
Avoiding aspirin altogether may be best for people taking Lipitor, particularly those with a history of bleeding disorders or other health conditions.
No Lipitor-related guidance and no 'avoid aspirin altogether' recommendation are present in the supplied label excerpts.
People taking high doses of aspirin or with a history of bleeding disorders should be cautious when taking aspirin with Lipitor.
No Lipitor-related caution language is present in the supplied label excerpts.
If a person has a history of bleeding disorders, it is best to avoid taking aspirin with Lipitor.
No Lipitor-related contraindication/avoidance statement is present in the supplied label excerpts.
If a person is taking a high dose of aspirin, taking it with Lipitor increases the risk of bleeding and other side effects.
No Lipitor-related risk language is present in the supplied label excerpts.
If a person has kidney disease, taking aspirin with Lipitor can increase the risk of kidney damage.
No Lipitor-related kidney risk language is present in the supplied label excerpts.
If a person has liver disease, taking aspirin with Lipitor can increase the risk of liver damage.
No Lipitor-related liver risk language is present in the supplied label excerpts.
Taking aspirin with Lipitor when taking a different type of antiplatelet medication is possible, but it is essential to talk to a doctor before doing so.
No interaction guidance regarding combining with other antiplatelet medications is present in the supplied label excerpts, and Lipitor is not addressed.
Contradictions
Low
AI Statement
Taking aspirin with Lipitor can reduce the risk of stroke in people who are at high risk.
Label Reference
Section 1 INDICATIONS AND USAGE (stroke-risk reduction is indicated for patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis; no 'high risk' wording and no Lipitor co-administration described).
Important Omissions
The response does not specify the FDA-approved product indication wording for Aspirin and Extended-Release Dipyridamole Capsules (TIA or completed ischemic stroke due to thrombosis) and instead mixes in unrelated 'Lipitor' claims.
Importance:
Moderate
No FDA label-supported dosage/administration safety details are provided for the referenced Aspirin and Extended-Release Dipyridamole Capsules (e.g., twice-daily dosing and 'not interchangeable' caution for individual components).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Most co-administration risk/benefit statements involve Lipitor and kidney/muscle/liver/bleeding risks that are not supported by the provided prescribing information excerpts (which are for a different aspirin/dipyridamole product and do not address Lipitor/atorvastatin interactions).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Lipitor-related mechanism and interaction/safety claims are unsupported because the supplied label excerpts do not cover Lipitor/atorvastatin or aspirin–Lipitor interaction details.
Suggested Improvement
Restrict claims to what is supported in the provided prescribing information for Aspirin and Extended-Release Dipyridamole Capsules (Section 1 stroke-risk reduction for TIA/completed ischemic stroke due to thrombosis; supported clinical study findings; and label-quoted dosage/administration statements). Remove or qualify all Lipitor/atorvastatin-specific assertions unless the corresponding atorvastatin prescribing information is supplied and verified.